For most of the past five years, artificial intelligence in drug discovery has lived largely in pilot programs: a promising proof-of-concept here, a narrow molecule-screening tool there, celebrated in press releases but rarely load-bearing in an actual development pipeline. That era appears to be ending. Industry tracking now counts more than 170 AI-discovered drug candidates in active clinical development, a figure that would have seemed implausible even three years ago, and pharmaceutical companies are beginning to restructure entire R&D functions around AI platforms rather than bolting AI tools onto existing workflows. The distinction matters. A pilot can be quietly shelved when it disappoints. A platform that a company has rebuilt its discovery process around cannot be, which is why 2026 is emerging as the year the industry’s rhetoric about AI-driven drug discovery finally has to be tested against production-scale results.
The most credible progress has come in target identification and lead optimization, the early stages of discovery where AI’s pattern-recognition strengths align well with the underlying problem: sifting enormous datasets of genomic, proteomic, and chemical information to identify promising biological targets and then refining candidate molecules against those targets far faster than traditional medicinal chemistry allows. Several AI-native biotech companies, along with AI divisions inside major pharmaceutical firms, report discovery timelines compressed from the traditional four-to-six-year window down to twelve to eighteen months for reaching a clinical candidate. Compression at this stage is real and well-documented across multiple independent programs, which is precisely why it is the part of the AI drug-discovery story least in dispute.
Where the promises still noticeably outrun the practice is later in the pipeline, particularly in clinical trial design and patient recruitment. AI-driven patient matching, which promises to identify eligible trial participants faster and build more representative cohorts, remains hampered by the same problem that has dogged healthcare AI broadly: fragmented, inconsistently formatted electronic health records across hospital systems and countries. Vendors selling AI-powered recruitment tools report meaningful improvements in enrollment speed for trials that already have clean, centralized data infrastructure, but for the majority of health systems that do not, the tools deliver far less than the marketing suggests. Similarly, AI-assisted trial design, using predictive modeling to optimize dosing schedules and endpoint selection, has produced genuine wins in specific therapeutic areas such as oncology, where biomarker data is relatively rich, but has been far less transformative in areas like psychiatry, where the underlying biology is less well characterized and the data AI models need simply does not exist at the same resolution.
The 170-plus AI-discovered drugs now in clinical trials also deserve a more careful reading than the headline figure invites. Being AI-discovered does not mean AI-validated; these candidates still have to clear the same Phase I, II, and III hurdles as any conventionally discovered molecule, and the attrition rate through clinical trials for AI-discovered candidates has not yet been definitively shown to be lower than for traditionally discovered ones, largely because the cohort is still too young and too small to generate statistically meaningful comparisons. The genuine claim the industry can make right now is that AI has compressed and cheapened the discovery phase, not that it has solved the much harder and more expensive problem of clinical validation, where most drug development costs and most drug failures actually occur.
What is different about 2026 compared to the pilot-heavy years before it is the organizational commitment behind the technology. Major pharmaceutical companies are consolidating what were previously scattered AI initiatives, often run by innovation labs with limited authority, into centralized platforms with dedicated budgets, executive sponsorship, and direct integration into core discovery workflows. This matters because pilot programs tend to be evaluated on novelty and promise, while platforms embedded in production workflows get evaluated on whether they actually move a drug through the pipeline faster and cheaper than the process they replaced. That harder standard of evaluation is now being applied at scale for the first time, and the results emerging from it, rather than from marketing materials, will determine whether AI drug discovery’s next phase lives up to its first one.
For India’s pharmaceutical and biotech sector specifically, this platform shift carries a distinct opportunity. India’s strength in software engineering and data science, combined with a pharmaceutical manufacturing base already comfortable operating within global regulatory frameworks, positions Indian companies well to build or license AI discovery platforms rather than simply using tools built elsewhere. Several Indian biotech firms and GCC-based teams are already contributing to AI-driven discovery programs for multinational partners, and the technical talent developing inside those partnerships is the same talent that could eventually anchor India’s own AI-native drug discovery companies, provided the capital and regulatory support exist to let that talent build independently rather than exclusively in service of foreign platforms.
The honest assessment, heading into the rest of 2026, is that AI has earned its place as a genuine tool in early-stage drug discovery, with compressed timelines and lower discovery costs that are no longer speculative. It has not yet earned the broader claim, still common in industry marketing, that it is fundamentally reshaping clinical development or patient recruitment at scale. Distinguishing between those two claims, rather than treating AI drug discovery as a single undifferentiated success story, is the discipline the industry now needs to apply to its own narrative.
– Dr Jagan Mohan Somagoni
